The medication preference screen lists four name-brand options Wegovy, Wegovy Pill , Zepbound, and Ozempic with a footnote beneath the list stating that The FuturHealth program includes access to both branded medications and customized, compounded medications based on what your clinician determines is medically appropriate and necessary for you
PMC 12446177
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
TrimRX prescribes GLP-1 receptor agonists: primarily semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound)
Image Credit: Pingpoy / Shutterstock Vasoplegic syndrome Vasoplegic syndrome refers to vasodilative shock that can present as severe hypotension, tachycardia, altered cardiac output, and/or reduced pulmonary pressure
The compounding-relevant chronology is also part of the public record: in February 2025 the FDA issued a declaratory order resolving the previously declared shortage of semaglutide injection products, with enforcement-discretion periods for 503A and 503B compounding concluding later that spring [8]
